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Maintaining homeostasis within any tis-
sue, including breast, exhibits striking
similarities to keeping a society civilized.
In both cases, fostering balanced and
functional relationships among members
is crucial to achieve harmony. The princi-
pal function of the normal breast is to
produce milk when needed. To achieve
this, multiple cell types communicate and
alter each other’s behavior within a
microenvironment with which they share
a reciprocal relationship. Milk produced
by the layer of luminal epithelial cells is
secreted into the ductal lumen and is
transferred along the duct with the help
of contractile myoepithelial cells that sur-
round the luminal epithelial cells. The
double-layered ductal or acinar struc-
tures are encapsulated within a base-
ment membrane (BM) in the normal
breast. The compartment outside the
ductal tree contains stromal-type extra-
cellular matrix (ECM) components such
as collagen I and elastin, adipose cells,
fibroblasts, immune cells such as leuko-
cytes and mast cells, and blood vessels.
The confined nature of the “double-lay-
ered tube” within the surrounding BM,
and the exquisitely choreographed inter-
actions among the epithelial cells, the
BM itself, and the surrounding stroma,
are all necessary for the organization
and architecture of the breast, which in
turn are necessary for its functional
integrity (Bissell et al., 2003).
In a society, loss of values that keep
cohesive interactions can lead to
breakup of the infrastructure and devel-
opment of rogue elements that escape
societal boundaries. Similarly, perturba-
tions in stromal-epithelial or cell-ECM
interactions and changes in hormonal
and cytokine milieu can initiate cascades
of events and responses, the end result
of which could be loss of polarity and dis-
ruption of the epithelial compartment
within the BM, leading to invasion, a hall-
mark of malignancy. The progression
from normal to malignant breast is
defined by pathological stages as deter-
mined by histological and cellular char-
acteristics of the tissue. Hyperplasia
(usual or atypical), ductal carcinoma in
situ (DCIS), and invasive carcinoma are
some of the easily decipherable stages
of breast cancer progression (Figure 1).
Acquisition of malignancy is accompa-
nied by changes in cell morphology,
function, and genome integrity, as well
as metaplastic changes in cell behavior
such as epithelial-to-mesenchymal tran-
sition and fibroblast-to-myofibroblast
conversions in the stroma (Ronnov-
Jessen et al., 1995). Most malignant
tumors are a disorganized mass of cells
and stromal components constantly rein-
venting themselves as “new organs”
(Bissell and Radisky, 2001).
Defining the processes by which a
functional, hormone-responsive gland,
wired to produce life-promoting milk,
turns into a malignant time bomb
requires a complete understanding of
both the functions of the individual cell
types and how they interact with each
other and with their microenvironment.
Since the majority of breast tumors
express luminal epithelial cell markers,
most of the work done in delineating the
molecular determinants of breast cancer
progression has so far focused on this
epithelial cell type. However, it is becom-
ing increasingly clear that all cell types
and stromal components will need to be
studied in order to get a complete and
accurate picture of malignant transfor-
mation. For example, myoepithelial cells
have been emerging as a crucial compo-
nent of breast function, and were shown
to have a gene expression profile which
implicated them as possible architectural
tumor suppressors of the breast (Barsky,
2003; Gudjonsson et al., 2002; Jones et
al., 2004).
A comprehensive study in this issue
of Cancer Cell by Allinen et al. (2004)
has taken this approach to determine the
molecular alterations that accompany
progression from normal to malignant
phenotype in the luminal epithelial,
myoepithelial, and stromal components
of the breast. In order to study all cell
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Progression from normal to malignant phenotype involves aberrations in the reciprocal interactions of multiple cell types
with each other and with other components of the microenvironment. In this issue of Cancer Cell, Allinen et al. (2004)
demonstrate that progression to breast cancer involves genotypic as well as gene expression changes that are cell type-
specific, suggesting that targeted therapies delivered to the tumor may need to include drugs targeted not only to the
tumor cells, but also to the other cell types in the tumor microenvironment.
Figure 1. Genetic and gene expression changes in breast cancer progression are cell type-
specific
Progression from the normal tissue architecture to ductal carcinoma in situ (DCIS) to invasive
cancer involves changes in and interactions among (shown by yellow arrows) the double-lay-
ered epithelium of luminal epithelial cells on the inside (red) and myoepithelial cells on the out-
side (blue) enclosed within a basement membrane (green); there are changes also in the
stromal component which contains fibroblasts (light blue), adipose, immune, and endothelial
cells (not shown), and stromal ECM (black mesh). DCIS contains disorganized, hyperproliferat-
ing luminal epithelial cells and an aberrant stroma with conversion of fibroblast to myofibrob-
lasts (white), but an apparently intact basement membrane. Invasive carcinoma is defined by
loss of BM integrity, loss of myoepithelial cells, and additional cell type conversions such as
epithelial-to-mesenchymal transition (from a red cell to a pink cell). Luminal epithelial cells are
prominent in invasive cancers and are genomically unstable, whereas myoepithelial cells show
the most significant gene expression changes in progression but no apparent genomic instabil-
ity. Paracrine interactions between myoepithelial and luminal epithelial cells that involve
chemokines CXCL12 and CXCL14 enhance cell proliferation, migration, and invasion, starting
at the DCIS stage.
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types involved in breast cancer progres-
sion, and to do so without altering their
properties during the process of isolation
from the breast, Kornelia Polyak’s group
improved existing protocols (Page et al.,
1999; Pechoux et al., 1999) to obtain not
only purified luminal epithelial and
myoepithelial cells but also endothelial
cells, leukocytes, and myofibroblasts.
The remaining fraction was used as a
source of semipurified fibroblasts, since
no specific fibroblast cell surface marker
is yet available. Cells isolated from nor-
mal, in situ carcinoma, or invasive carci-
noma were examined by array CGH and
SNP arrays to determine genetic alter-
ations, and by SAGE to determine gene
expression profiles. Results for both the
genomic integrity and the gene expres-
sion analysis clearly demonstrate the
utility of studying each cell type sepa-
rately, with particular emphasis on the
significance of myoepithelial cells in
tumor progression. Interestingly, Alinnen
et al. found that unlike luminal epithelial
cells, myoepithelial cells displayed 
no detectable genomic abnormalities.
However, the most dramatic gene
expression changes in tumor progres-
sion occurred in myoepithelial cells
already at the DCIS stage.
Of the gene classes that are altered ,
Allinen et al. focus on chemokines for fur-
ther analysis, and find that expression of
CXCL12 and CXCL14 is highly upregu-
lated in myoepithelial cells and myofi-
broblasts in DCIS and invasive
carcinomas. By immunohistochemistry,
CXCL14 was found also in luminal
epithelial cells in a subset of invasive
tumors and malignant breast cancer cell
lines. Allinen et al. demonstrate that
CXCL14 can bind to both normal and
malignant luminal epithelial cells and cell
lines, suggesting the presence of a
receptor on luminal cells. CXCL12 and
CXCL14 could also increase cell prolifer-
ation, migration, and invasion of luminal
epithelial cell lines in culture. These find-
ings are consistent with previous studies
that implicate altered chemokine expres-
sion levels as an indicator of progression
to tumorigenicity (Porter et al., 2001,
2003) and metastatic capacity (Muller et
al., 2001), and suggest a paracrine
mechanism of action. Inhibition of
CXCR4, the receptor for CXCL12, has
been shown to prevent breast cancer
metastasis (Liang et al., 2004). Allinen et
al. raise the possibility of using such
inhibitors to treat early-stage breast can-
cers as well as the advanced metastatic
cancers.
Another important conclusion of
Allinen et al.’s studies is the demonstra-
tion that sufficient material can be
obtained to study gene expression and
changes in genotype in most cell types
within the breast tissue, using the techni-
cal improvements introduced. Even
though the number of tissue samples
was small, it was possible to discover cell
type-specific markers of breast cancer
progression. Such studies would have
enormous implications for targeted ther-
apies should a large enough number of
samples become available. A compre-
hensive profiling of the molecular deter-
minants of breast tumor progression
would also require access to tissues
from the intermediate stages of tumor
progression from the same patient, given
the known heterogeneity of the tumori-
genic process. These, however, are hard
to come by in human tumors. Indeed, we
have very few studies where such a
requirement has been fulfilled for breast
tumors. The Polyak group now provide
the valuable proof-of-principle study to
motivate large scale efforts to accom-
plish this goal at a statistically significant
manner for person-specific, as well as
cell type-specific, therapies.To thorough-
ly understand breast cancer with all its
cell type-specific and other microenvi-
ronmental changes, joint efforts and
multi-institutional collaborations to pool
tissues are necessary.We now know that
conquering cancer will also take a
village!
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